Replies to post #17114 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

There is no compliance issue on the Glatopa (20mg/40mg) production line; the problem is elsewhere in the facility.

[DFRAI]

Basically its a case of FDA punishing all for Pfizer not taking care of some issues...these MNTA type clients should move to better facilities if they are expected to survive